Fig. 3
From: The chromatin guardian ATRX is a strong prognostic biomarker in melanoma
Number of proliferating melanoma cells per TMA core quantified by Mib-1 immunohistochemistry. Significant difference between primary melanomas and metastases (A). Number of vessels per TMA core quantified by CD34 immunohistochemistry. Significant difference between primary melanomas and metastases (B).
